{"Title": "Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa", "Year": 2017, "Source": "J. Infect. Dis.", "Volume": "215", "Issue": 9, "Art.No": null, "PageStart": 1362, "PageEnd": 1365, "CitedBy": 38, "DOI": "10.1093/infdis/jix089", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85022002176&origin=inward", "Abstract": "\u00a9 The Author 2017. Published by Oxford University Press for the Infectious Diseases Society.To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub- Saharan Africa (SSA) for a range of program situations. We applied this to SSA through the Spectrum-Goals model. In a situation in which current levels of pretreatment HIVDR are over 10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of new infections (450 000), and 8% ($6.5 billion) of ART program costs in SSA in 2016-2030 will be attributable to HIVDR.", "AuthorKeywords": ["cost", "death", "drug resistance", "HIV", "incidence", "mathematical model"], "IndexKeywords": ["Adolescent", "Adult", "Africa South of the Sahara", "Anti-HIV Agents", "Cohort Studies", "Drug Resistance, Viral", "HIV Infections", "HIV-1", "Humans", "Incidence", "Middle Aged", "Models, Theoretical", "Young Adult"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85022002176", "SubjectAreas": [["Immunology and Allergy", "MEDI", "2723"], ["Infectious Diseases", "MEDI", "2725"]], "AuthorData": {"35372648800": {"Name": "Phillips A.N.", "AuthorID": "35372648800", "AffiliationID": "60022148", "AffiliationName": "Institute for Global Health, University College London (UCL), Royal Free Campus"}, "35361474300": {"Name": "Cambiano V.", "AuthorID": "35361474300", "AffiliationID": "60022148", "AffiliationName": "Institute for Global Health, University College London (UCL), Royal Free Campus"}, "54385574100": {"Name": "Nakagawa F.", "AuthorID": "54385574100", "AffiliationID": "60022148", "AffiliationName": "Institute for Global Health, University College London (UCL), Royal Free Campus"}, "35241051500": {"Name": "Stover J.", "AuthorID": "35241051500", "AffiliationID": "60138527", "AffiliationName": "Avenir Health"}, "26660482400": {"Name": "Jordan M.R.", "AuthorID": "26660482400", "AffiliationID": "60023143", "AffiliationName": "Tufts University, School of Medicine"}, "7201727367": {"Name": "Pillay D.", "AuthorID": "7201727367", "AffiliationID": "60022148", "AffiliationName": "Division of Infection and Immunity, University College London"}, "7203078259": {"Name": "Doherty M.", "AuthorID": "7203078259", "AffiliationID": "60027142", "AffiliationName": "World Health Organisation"}, "8545760800": {"Name": "Bertagnolio S.", "AuthorID": "8545760800", "AffiliationID": "60027142", "AffiliationName": "World Health Organisation"}, "57193543168": {"Name": "Revill P.", "AuthorID": "57193543168", "AffiliationID": "60016418", "AffiliationName": "Centre for Health Economics, University of York"}}}